ARQT
Arcutis Biotherapeutics Inc
26.50$
+1.2%
vs. previous close
Closing price · As of: Sep 17, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +16.5% | +40.2% | -7.1% | -1.7% | -20.2% | -1.4% | +2.4% | +5.3% | +16.7% | +6.2% | +6.2% | |
| – | +17.4% | +41.7% | -7.2% | -2.5% | -20.7% | -3.6% | +2.8% | +4.9% | +17.8% | +6.5% | +6.8% | |
| – | -17.7% | +115.7% | -55.5% | +58.9% | -47.1% | -25.6% | +37.6% | -35.5% | -8.9% | -19.0% | -1.8% | |
| – | +19.7% | +48.8% | -10.2% | -8.9% | -31.0% | -13.1% | -3.5% | 0.0% | +15.7% | +1.4% | +6.5% | |
| – | +32.9% | +44.0% | +16.8% | +38.5% | +21.5% | +16.9% | +24.9% | +7.9% | +27.0% | -1.3% | +7.5% | |
| – | -5.6% | +0.9% | +4.8% | +1.0% | +3.6% | +14.4% | -1.7% | +37.3% | +1.0% | +65.2% | +4.0% | |
| – | -2.8% | -2.9% | -3.0% | +61.5% | -3.2% | +74.1% | -3.4% | -3.5% | -3.7% | -3.8% | -4.0% | |
| – | +2.6% | +0.4% | +1.9% | +8.7% | -31.8% | +5.3% | +6.0% | -0.3% | +14.4% | +11.0% | -0.9% | |
| – | +11.4% | +1.4% | +8.5% | +235.8% | -53.0% | +12.5% | +14.1% | -4.0% | +30.1% | +25.7% | -1.8% | |
| – | +2.8% | +2.9% | +2.8% | +12,810.0% | -99.2% | +2.7% | +18.8% | +0.0% | +0.0% | +695.0% | -12.6% | |
| – | -9.0% | +8.1% | -38.8% | +143.3% | -26.4% | +72.5% | -38.5% | -61.6% | +116.2% | +46.0% | -63.9% | |
| – | +0.5% | +0.5% | +0.5% | -48.4% | +2.0% | +0.4% | -0.5% | +0.4% | +0.4% | -6.0% | +0.5% | |
| – | +89.8% | +153.7% | -17.1% | -16.0% | +0.6% | -9.4% | -2.6% | +13.7% | +19.9% | +0.1% | +16.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +50.0% | +19.9% | +11.2% | +0.7% | -2.7% | +4.2% | +0.8% | +4.6% | +2.1% | -4.6% | +5.1% |
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.